e-Drug3D

2123

LANDIOLOL

INN
LANDIOLOL

cas 133242-30-5

CLASS

CARDIOVASCULAR
BETA ADRENERGIC ANTAGONIST
SHORT-TERM REDUCTION OF VENTRICULAR RATE IN ADULTS WITH SUPRAVENTRICULAR TACHYCARDIA INCLUDING ATRIAL FIBRILLATION AND ATRIAL FLUTTER

ROUTE (list)

INTRAVENOUS

ATC code

C07AB14

PK parameters

Cmax 1.9 MICROMOLAR
VD 26 LITER (65 KILOGRAM)
Cl 222 LITER / HOUR (65 KILOGRAM)
PPB 10 PERCENT
t1/2 0.075 HOUR

Solubility

VERY SOLUBLE IN WATER

Target

TARGET BETA-1 ADRENERGIC RECEPTOR

DrugCentral

Beta-1 adrenergic receptor UNIPROT P08588 ADRB1_HUMAN

Download SDF file

Benzenepropanoic acid, 4-[(2S)-2-hydroxy-3-[[2-[(4-morpholinylcarbonyl)amino]ethyl]amino]propoxy]-, [(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl ester

Formula:
C25H39N3O8

Calculated chemical properties:

MW 509.59
NB_atoms 36
XLogP 0.69
PSA 134.44
NB_HD 3
NB_HA 11
fsp3 0.68
Lipinski(0=no;1=yes) 0

FDA
NDA 217202 (label) INN (LANDIOLOL HYDROCHLORIDE) RAPIBLYK (AOP HLTH US) APPROVAL= AP YEAR= 2024 NEWMOLECULARENTITY